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ABSTRACT
Background and Objectives: Patent foramen ovale (PFO) has been implicated in the pathogenesis of cryptogenic stroke or 
transient ischemic attack (TIA) due to paradoxical embolism, and in the pathogenesis of migraine. This paper reports the 
intermediate and long-term results of transcatheter closure of PFO associated with cerebrovascular accidents (CVAs), TIAs 
and migraine, using the Amplatzer PFO occluder. This paper also reports a case of pulmonary embolism which developed 
in one patient after PFO closure. Subjects and Methods: From January 2003 to May 2010, 16 patients with PFO (seven males 
and nine females) with a history of at least one episode of cryptogenic stroke/TIA, CVA, or migraine and who underwent per-
cutaneous transcatheter closure of PFO using the Amplatzer occluder. All the procedures were performed under general 
anesthesia and were assisted by transesophageal echocardiography. Results: The device was implanted without any signifi-
cant complications in all the patients, and the PFOs were effectively closed. At an average follow-up period of 54 months, the 
15 patients with TIA/CVA had no recurrence of any thromboembolic event. The symptoms in one patient with migraine sub-
sided after occlusion of the PFO. In this study, pulmonary embolism occurred five months after PFO closure in one patient, 
but the cause of pulmonary embolism was not identified. However, it is believed that the pulmonary embolism occurred with-
out stroke recurrence because occlusion of the PFO was performed when the patient had a stroke event. Conclusion: It can 
be concluded that according to the intermediate and long-term follow-up results, transcatheter PFO closure is an effective 
and safe therapeutic modality in the prevention of thromboembolic events, especially in the patients with cryptogenic st-
roke/TIA, and PFO closure is helpful in the treatment of migraine. However, this study involved a small number of patients 
and also the follow-up period was not long enough. Hence, randomized, controlled trials are necessary to determine if this ap-
proach is preferable to medical therapy for the prevention of recurrent stroke or as primary treatment for patients with mi-
graine headache. (Korean Circ J 2011;41:356-362)
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Introduction
The etiology of ischemic stroke remains unknown in upto 
40% of patients, despite an extensive diagnostic evaluation, 
and is referred to as cryptogenic.
1) Patients with cryptogenic 
stroke have a higher prevalence of patent foramen ovale (PFO) 
than patients with stroke of determined cause.
2) The relation-
ship between paradoxical (right-to-left) embolism through a 
PFO and stroke remains controversial because of variability 
in the reported stroke risk in patients with PFOs.
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assessment study with transesophageal echocardiography 
(TEE) found a PFO in 25.6% of healthy subjects.
4) Excess at-
rial septal tissue in the region of the fossa ovalis causes incr-
eased movement of the septum during respiration. This find-
ing is classified as atrial septal aneurysm (ASA) when it had 
an excursion greater than 10 mm into the right or left atrium. 
PFO with and without ASA was recognized as a potential risk 
factor for ischemic stroke only in the past two decades. Also, 
patients who have suffered a cryptogenic stroke related to 
PFO may have a stroke recurrence,
5)6) a risk that is particularly 
pronounced in patients with PFO and associated ASA.
7)8) PFO 
is also associated with migraine with aura. Recent retrospec-
tive studies indicate a reduction in migraine frequency after 
PFO closure. Therapeutic options for PFO range from antipla-
telet therapy to surgical or endovascular closure of the atrial 
shunt. Transcatheter closure of PFO was recently introduced 
in clinical practice. The goals of PFO closure are to prevent 
neurological events and to avoid the need for long-term an-
ticoagulant therapy.
9) This study reports the intermediate and 
long-term results of transcatheter closure of PFO associated 
with paradoxical embolism, which led to cryptogenic stroke 
or transient ischemic attack (TIA), and migraine, using the 
Amplatzer PFO occluder at the authors’ hospital. This paper 
also reports a case of pulmonary embolism that developed in 
one patient irrespective of PFO closure. 
Subjects and Methods
Patient population
From January 2003 to June 2010, of a total of 16 patients, 15 
patients with PFO (seven males, and eight females) were re-
ferred for percutaneous closure of PFO. The primary reasons 
for referral were stroke {12/16 (75%)}, and TIA {3/16 (18%)}. 
The symptoms included motor deficit in eight patients (50%), 
aphasia in one patient (6%), visual disturbances in four pa-
tients (25%), headache in four patients (25%), stupor in one 
patient (6%), and dysarthria in three patients (18%) (Table 3). 
The patients’ conditions were initially diagnosed by neurolo-
gists. One patient who had migraine was referred for percu-
taneous PFO closure from pediatric outpatient department. 
Multiple thromboembolic events occurred in six patients 
prior to transcatheter device closure of PFO. The vascular risk 
factors were infrequent (Table 1). Cryptogenic stroke/TIA 
was present in eight patients (53%). ASA was present in sev-
en patients (43%). The electrocardiographic findings before 
the procedure were all non-specific. Cryptogenic stroke was 
defined by the presence of a transient or permanent neuro-
logical deficit with associated magnetic resonance imaging 
(MRI) evidence of an embolic lesion, in the absence of a clear 
cause.
10) Ischemic stroke was defined as a cerebrovascular 
event with neurological symptoms lasting more than 24 hours 
without any sign of a primary cerebral hemorrhage. TIA was 
defined as a new neurological deficit with complete cessa-
tion of symptoms for 24 hours in the absence of lesions in the 
MRI.
11) Migraine was defined as a severe recurring headache 
lasting from 4 to 24 hours, characterized by sharp pain, and 
is often accompanied by nausea, vomiting, and visual distur-
bances.
Echocardiography
TEE was performed to detect PFO. An agitated saline bub-
ble study was conducted to evaluate the degree of the right-to-
left shunt at rest and after the Valsalva maneuver. The air bub-
ble test was performed in all the patients, and all of them sh-
owed positive results except for one patient, wherein the result 
was not positive because of poor co-operation.
Device
The Amplatzer PFO occluder device was used in this study. 
It was constructed from the nitinol wires and consisted of two 
flat disks with a 3-mm long thin connecting waist. The right 
atrial disk was larger than the left atrial disk, which made it 
suitable for the occlusion of PFO. In this study, three sizes of 
the device were used, 18 mm, 25 mm, and 35 mm (Fig. 1).
Implantation procedure
The full procedure was performed under general anesthe-
sia and was assisted by TEE through the femoral artery and 
vein. The NIH catheter (Cordis Europa N.V., Roden, The Ne-
therlands) was advanced through an 8-Fr sheath, and pul-
monary venous angiography was performed in LAO 45° view 
via the femoral vein. During TEE monitoring, the size of PFO 
with or without ASA was estimated using a balloon catheter 
(Boston Medical Corporation, Boston, MA, USA), and the 
size of the device was selected accordingly. The Amplatzer 
PFO occluder was implanted in the interatrial septum with 
great care under the water seal to prevent air embolism. 
Before and after the procedure, all the patients received in-
travenous heparin to prevent thrombus formation, and the 
transseptal sheaths were removed after the activated coagu-
lation time stabilized (activated clotting time <140 seconds) 
Fig. 1. Amplatzer PFO occluder (AGA Medical Corporation) is a 
self expandable, double disc device made from Nitinol wire mesh. 
The two discs are linked together by a short connecting waist al-
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with manual compression for achieving hemostasis, and an 
antidote was not used.
TEE was performed before the patient was discharged, 
mostly at two days after the procedure. After the occlusion of 
PFO, the air bubble test was performed again and all the pa-
tients showed negative results. After the procedure, 100 mg/
day of aspirin for six months was prescribed for all the pa-
tients.
Follow-up
All the patients returned for regular check-up visits at one, 
two, six and twelve months after the procedure, and yearly th-
ereafter. Each patient underwent at least one TEE examina-
tion during the first six months after the procedure to confirm 
the adequacy of placement of the device and to document the 
absence of a residual shunt or thrombus formation on the de-
vice. Frequent clinical follow-ups at six- to 12-month inter-
Table 1. Clinical characteristics of patients 
Patient (no.) Age (years) Sex  Cardiac abnormality  Vascular risk factor  Qualifying event 
1 51 F PFO (30 mm) with ASA Hypercholesterolemia TIA
2 37 F PFO (25 mm)  None  CVA, TIA
3 46 F PFO (12 mm)  None CVA
4 39 M PFO (21 mm) with ASA Alcohol, smoking  CVA
5 20 M  PFO (18.7 mm) with ASA Smoking  CVA
6 44 F PFO (12.5 mm)  None TIA 
7 50 F PFO (18.7 mm) with ASA None  CVA
8 41 M PFO (18 mm)  Alcohol, smoking  CVA
9 47 M PFO (20 mm)  Alcohol, smoking, hypertension TIA 
10 69 F PFO (17 mm) with ASA None  CVA
11 59 F PFO (13.5 mm) with ASA None CVA
12 51 M PFO (12.5 mm) Hypertension CVA
13 50 M PFO (13 mm) None CVA
14 43 M PFO (12.5 mm) Alcohol, smoking CVA
15 43 F PFO (11.5 mm) with ASA None CVA
16 10 F PFO (9 mm) None Migraine 
PFO: patent foramen ovale, ASA: atrial septal aneurysm, TIA: transient ischemic attack, CVA: cerebrovascular accident
Table 2. Results of the transcatheter closure of PFO with the amplatzer PFO occluder
Patient
 (no.)
Fluoroscopy time
(minutes)
Procedural 
complication
Follow-up period
(after PFO closure)
Recurrence 
of  TIA/Stroke
Residual 
shunt 
Amplatzer 
device size 
1 35.6 Transient ST elevation 73 months None None 35 mm
2 20.5 None 73 months None None 35 mm
3 28.0 None 77 months None None 25 mm
4 33.1 None 77 months None None 35 mm
5 24.6 None 85 months None None 35 mm
6 29.5 None 88 months None None 25 mm
7 16.0 None 70 months None None 25 mm
8 12.0 None 66 months None None 25 mm
9 10.3 None 61 months None None 25 mm
10 10.0 None 61 months None None  25 mm
11 20.0 None 32 months None None 18 mm
12  15.0 None 27 months None None 18 mm
13 15.0 None 23 months None None 18 mm
14 15.0 None 16 months None None 25 mm
15 10.0 None 10 months None None 25 mm
16 15.0 None 10 months None None 18 mm
PFO: patent foramen ovale, TIA: transient ischemic attack, Lt: left, Rt: rightJu Hee Yoon, et al.   359
vals were performed with a questionnaire to evaluate the sy-
mptoms, and evidence of recurrent thromboembolic events. 
A detailed history of new neurological incidents was taken, 
and physical as well as neurological examinations were per-
formed during each follow-up visit. 
Results
Patient characteristics
The clinical variables of the group that underwent PFO clo-
sure are listed in Table 1. There were seven male, and nine fe-
male patients. Their median age was 43.8 years (range, 10.2-
69.8 years). 
Procedure results
The procedure results are shown in Table 2. The device was 
successfully implanted in all the patients under general anes-
thesia. The sizes of the Amplatzer devices used were 18 mm 
(n=4), 25 mm (n=8), and 35 mm (n=4). The mean duration 
of the fluoroscopy time was 19.3 minutes (range, 10.0-35.6 
minutes). In all the patients, the PFO was closed completely 
(Fig. 2A). TEE and chest PA, which were performed before 
the patients were discharged from the hospital, confirmed 
the correct placement of the device in the interatrial septum in 
all the patients. No procedural complications were observed. 
Follow-up
All the patients were followed up for a mean period of 54 
months (range: 10-88 months). There were no recurrent epi-
sodes of cerebrovascular accidents or TIA. Of all the 16 pa-
tients, the initial symptoms almost subsided in 10 patients 
(62.5%), due to which the anticoagulation therapy was dis-
continued. Three patients were in a minimally assisted gait 
state, and three patients were in a assisted daily life state, or 
had lt. hemianopsia, and dysarthria, respectively (Table 3). 
Three patients had taken anticoagulation therapy to prevent 
the recurrence of cerebrovascular events. A follow-up TEE 
was performed during the first six months after the proce-
dure, and no residual shunt was observed. None of the pa-
tients documented atrial fibrillation before or after the im-
plantation of the device. No dislocation of the device or 
fracture of the occluder construction was detected (Fig. 2B). 
The symptoms in the patient who had migraine subsided af-
ter occlusion of the PFO. However, the patient who develop-
ed pulmonary embolism was an exceptional case. A 55-year-
old woman who had an acute infarction in the left middle ce-
Fig. 2. PFO occlusion using the Amplatzer PFO occluder. A: the 
selective superior vena cava angiography after the implantation 
of Amplatzer PFO occluder (arrow). B: the simple chest radiogra-
phy, lateral view 5 months after PFO closure (arrow). PFO: patent 
foramen ovale.
A   B
Table 3. Presenting symptoms of patients with TIA or CVA 
Patient
  (no.)
Age
(years)
Sex Initial symptoms Residual symptoms
Follow-up period 
(after PFO closure)
1 51.2 F Tingling sensation in the Rt. hand None 73 months 
2 37.8 F Headache None 73 months
3 46.1 F Rt. sided motor weakness None 77 months 
4 39.6 M Diplopia None 77 months
5 20.6 M Lt. sided motor weakness, headache Minimally assisted gait 85 months
6 44.7 F Lt. sided motor weakness None 88 months
7 50.7 F Dizziness, Lt. sided motor weakness None 70 months
8 41.9 M Aphasia, Rt. sided motor weakness, Rt. homonymous hemianopsia None 66 months
9 47.8 M Dizziness, diplopia None 61 months
10 69.8 F Lt. sided motor weakness Assisted gait 61 months
11 59.1 F Stupor Assisted daily life 32 months
12 51 M Lt. hemianopsia, headache  Lt.hemianopsia 27 months
13 50 M Lt. sided motor weakness, dysarthria Dysarthria  23 months
14 43 M Rt. sided motor weakness, dysarthria Assisted gait  16 months
15 43 F Dysarthria None 10 months
16 10 F Migraine headache None 10 months 
TIA: transient ischemic attack, CVA: cerebrovascular accident, PFO: patent foramen ovale, Lt: left, Rt: right360   Intermediate and Long-Term Results of Patent Foramen Ovale Closure
rebral artery was admitted to the authors’ hospital due to the 
development of dysarthria and right-sided weakness, and 
recurrence of stroke was detected on an MRI scan (Fig. 3). 
The patient was referred to the Pediatric Department and she 
underwent PFO closure with an 18 mm Amplatzer PFO oc-
cluder. During a follow-up check-up at five months after the 
PFO closure, the patient had dyspnea and was readmitted to 
the hospital via the ER. The patient’s oxygen saturation was 
found to be 94-95%, and chest X-ray showed a prominent 
right hilum (Fig. 4). The 2D echocardiogram revealed severe 
pulmonary hypertension, right ventricular dysfunction, and 
tricuspid regurgitation {TR G (Ш)/VI; TR peak pressure: 
82.46 mmHg} (Fig. 5). Neither thromboembolism nor a sh-
unt was observed in this patient treated using the PFO Am-
platzer occluder (Fig. 6). However, acute pulmonary embo-
lism was found on the chest CT angiogram (Fig. 7). Hence, 
25000 UI bolus of heparin was injected, following which 12 
UI/kg/hr of heparin was infused. This protocol was discon-
tinued after the fourth day of heparin administration be-
cause the aPTT was 60-90 seconds and the international nor-
malized ratio was 2-3. The patient’s symptoms improved after 
two days of hospital admission. A lower extremity doppler 
sonography was performed to identify the cause of the pul-
monary embolism, but no deep vein thrombosis was detect-
ed. No sources for embolism were found either on the abdo-
minal pelvic CT or. Ten days after the pulmonary embolism, 
the previous RV dysfunction was no longer observed on the 
2-D echo, and the patient had slight sequelae.
Discussion
PFO has been implicated in the pathogenesis of cryptoge-
nic stroke and TIA due to paradoxical embolism, and in the pa-
thogenesis of migraine.
12) The increased risk of stroke in pa-
tients with migraine could be explained by the patients’ in-
creased propensity to paradoxical embolism.
2) Meta-analyses 
of observational studies have indicated that the prevalence of 
PFO is approximately three times higher in patients with cry-
ptogenic stroke and migraine than in the controls. Converse-
ly, the observational evidence indicates a two to three fold in-
creased prevalence of migraine and cerebrovascular events 
in PFO carriers.
12) The analysis of the 16 patients who under-
went percutaneous closure of PFO with Amplatzer devices 
demonstrated the relative safety of percutaneous transcathe-
Fig. 3. Recurrence stroke was detected on an MRI scan. A: 1st 
acute infarction in the left middle cerebral artery-left fronto-tempo-
ral lobe, insular cortex, and basal ganglia (arrow). B: 2nd acute in-
farction (2 months later)-left frontal lobe (arrow).
A   B
Fig. 4. Chest X-ray (sitting position) shows prominent right hilum 
and decreased pulmonary vascularity when the patient was admit-
ted again via emergency room with dyspnea, five months after the 
patent foramen ovale closure.
A   B  
Fig. 5. Patientsʼ 2D echocardiogram revealed severe pulmonary hypertension, right ventricular dysfunction, and tricuspid regurgitation. A: 
the 2D echocardiogram (2 chamber view) revealed right ventricular dysfunction (right ventricle is larger than the left ventricle). B: pulmonary 
hypertension and tricuspid regurgitation (arrow). 2D: 2-dimensional, RV: right ventricle, LV: left ventricle.
RV
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ter PFO closure in patients with cryptogenic stroke or TIA. 
Over the course of 54 months, 16 patients were referred for 
PFO closure. The primary reasons for referral was the history 
of embolic events in 15 patients, which was determined by 
the clinical diagnosis of TIA or stroke, as confirmed via MRI, 
and migraine in one patient. All the patients had PFO, and 
seven patients (43%) had ASA. Two recent TEE studies con-
firmed the increased prevalence of PFO and ASA in young 
patients who had experienced stroke due to unexplained cau-
ses.
13)14) In a meta-analysis of case control studies, Overell et 
al.
15) concluded that the relative risk of stroke compared with 
non-stroke controls increased by a factor of 1.83 {confidence 
interval (CI): 1.25-2.66} if a PFO was present. In the patients 
with both PFO and ASA, the relative risk of stroke was 4.96 
(CI: 2.36-10.39). Previous trials of transcatheter PFO closure 
(on a total of 538 patients) have documented a recurrence 
rate of 0-3.2% of stroke or embolism after a one-year follow-
up, depending on the device used.
16-19) Studies that involved 
newer devices, including the Amplatzer PFO occluder, have 
shown a recurrence rate of <1% of stroke and embolism and 
an occlusion rate of 96-100%.
17-19) The authors’ experience re-
vealed a 0% recurrence of embolic events in these 16 patients 
who underwent PFO closure, a 100% procedural success rate, 
and a combined complication rate of 0%, with a mean follow-
up period of 54 months (range: 10-88 months). However, em-
bolization remains one of the possible complications. Other 
serious complications that occur in less than 1% of cases are 
infection, erosion into the pericardium or aorta at the rim of 
the device, a new ASD caused by the tearing of the thin sep-
tum primum by the lower rim, atrial fibrillation, and palpit-
ations that are not common and usually subside spontane-
ously.
20)
In this study, one patient developed pulmonary embolism 
without a known cause, despite an extensive evaluation. If this 
patient had not been treated with the transcatheter closure 
device; the Amplatzer PFO occluder when she had a stroke 
recurrence (second attack), she would have had a third attack 
of stroke, rather than developing only pulmonary embolism. 
Therefore, it can be concluded that transcatheter closure of 
PFO with the Amplatzer PFO occluder appears to be a promis-
ing therapy for prevention of stroke in patients with a history 
of cryptogenic stroke or TIA. Also, this procedure had a high 
success rate, a low rate of complications, and a low frequency 
of recurrent systemic thromboembolic events, and it avoids 
the need for lifelong anticoagulation therapy. It especially 
seemed to have more benefits in those cases in which the pa-
tient was younger than 55 years, and had no identifiable cause 
of his/her thromboembolic event, except for a PFO with/with-
out ASA. In this study, the symptoms in one patient who had 
migraine subsided after the occlusion of PFO. Earlier studies 
have also indicated that migraine frequency might decrease 
after PFO closure.
21)22) Migraine improves spontaneously 
with age,
23) however, and any kind of intervention has a high 
placebo response in migraine, which can reduce the migraine 
frequency by upto 70%.
24)25) Thus, there is a debate on perform-
ing PFO closure for the prevention of migraine.
However, this study had several limitations. It involved a 
small number of patients who had cryptogenic stroke (n= 
12) or TIA (n=3) {eight patients (53%)} and migraine (n=1), 
and also the follow-up period was not long enough. Hence, 
randomized, controlled trials are necessary to determine if 
the proposed approach is preferable to medical therapy for 
the prevention of recurrent stroke or as a primary treatment 
for patients with migraine headache. 
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